Company intelligence / Profile preview
Lanier Biotherapeutics
Jefferson, Georgia, United Stateslanierbio.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Lanier Biotherapeutics has a robust preclinical pipeline of 11 first-in-class therapeutic antibodies targeting specialty diseases in retina/ophthalmology, type 2 inflammation/fibrosis (including respiratory and dermatological conditions), immuno-oncology and solid tumors. Lead programs include a multifunctional anti‑VEGF/IL‑17A antibody for retinal disease and an anti‑IL25 mAb for type 2 inflammatory conditions. No clinical results have been reported yet as all programs are preclinical.
- Therapeutic areas
- OphthalmologyOncologyImmunologyDermatology
- Modalities
- Monoclonal antibodies (mAbs)Antibody Drug Conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Alloy Therapeutics – licensing agreement for proprietary platform technologies
Beyond the preview
Go deeper on Lanier Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lanier Biotherapeutics.